AOD-9604 vs ipamorelin: what the human trial data actually shows

Last updated 2026-07-24

What are AOD-9604 and ipamorelin, and how are they different drugs?

AOD-9604 is a 15-amino-acid fragment of human growth hormone, specifically the C-terminal region (amino acids 176-191) that researchers identified as the part of the GH molecule responsible for fat metabolism, without the part that affects blood sugar and cell growth. The idea, going back to work summarized in a 2004 review in Current Opinion in Investigational Drugs, was to keep the lipolytic (fat-burning) piece of GH and drop the diabetogenic piece ^[1]. Ipamorelin is a completely different molecule: a five-amino-acid peptide that belongs to the growth hormone secretagogue class. It doesn't fragment GH at all. Instead it binds the ghrelin receptor (GHS-R1a) and prompts the pituitary to release the body's own GH, similar in concept to older secretagogues but described as more selective for GH release with less effect on cortisol and prolactin than earlier compounds in that class. So the comparison isn't apples to apples. AOD-9604 is a GH fragment that never became a full obesity drug. Ipamorelin is a GH-releasing peptide that works upstream, by nudging the pituitary rather than mimicking a piece of the hormone itself. If you're deciding between them, you're really deciding between two different theories of how to move fat metabolism, not two versions of the same product. For the full mechanism rundown, see the AOD 9604 peptide reference page.

Did AOD-9604 actually work in human obesity trials?

This is the part that gets buried in most marketing copy, so let's not bury it. AOD-9604 went through clinical development for obesity, and the fat-loss signal did not separate convincingly from placebo in the trial program. A 2004 review of the compound's development in Current Opinion in Investigational Drugs describes it as a metabolic fragment of GH under investigation for obesity, reflecting the state of the evidence at that point in its development ^[1]. A separate 2006 review of obesity drugs in clinical development situates AOD-9604 among the broader pipeline of anti-obesity candidates being tested around that era, most of which either stalled or were later withdrawn ^[2]. That's a fairly quiet paper trail for a compound that gets described online as a proven fat-loss agent. There's no large, published, peer-reviewed randomized controlled trial showing AOD-9604 beats placebo by a clinically meaningful margin on body weight or fat mass. If that trial existed and showed a strong effect, it would be the single most-cited paper in every AOD-9604 sales page on the internet. It isn't, because it doesn't show that. The honest summary: the fragment rationale is scientifically reasonable (isolate the lipolytic domain of GH, skip the diabetogenic domain), but reasonable rationale is not the same as a positive trial result. Development did not progress to FDA approval for obesity or any other indication. If you want more detail on what the trial record does and doesn't show, that lives on the AOD 9604 peptide hub page.

What does the evidence for ipamorelin actually look like?

Ipamorelin's evidence base is built on its identity as a growth hormone secretagogue, not on dedicated large-scale human fat-loss trials either. Recent reviews covering peptide therapeutics in orthopedic and sports medicine contexts, including a 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews on therapeutic peptides in orthopaedics and a 2026 review in Sports Medicine on approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, place ipamorelin and related GH secretagogues in the broader unapproved peptide category used off-label by athletes and in research settings, generally in the context of recovery and body composition claims rather than a validated fat-loss indication ^[3][4]. The mechanistic story for ipamorelin is more established than AOD-9604's in one specific sense: GH release itself is a well-documented physiological event, and secretagogues that reliably raise GH and downstream IGF-1 have decades of endocrinology behind that part of the pathway. What's not well established, for ipamorelin specifically, is a large randomized trial proving that this GH bump translates into significant fat loss in otherwise healthy adults using it for body composition. Most of what circulates is small studies, mechanistic work, or extrapolation from approved GH-axis drugs used for genuine GH deficiency, which is a different population and a different question. So neither peptide has the kind of trial file you'd want before paying for months of injections purely for fat loss. Ipamorelin's story is just built on a different, arguably more physiologically grounded, foundation.

AOD-9604 vs ipamorelin: side-by-side comparison

The table makes the core point visually: both compounds sit outside the approved drug system, and neither has a slam-dunk human fat-loss trial to point to. The differences are in mechanism and in how each interacts with drug testing, not in "one is proven and one isn't."

Is AOD-9604 or ipamorelin legal to buy and use?

Neither peptide is FDA-approved, and neither appears on the FDA's bulk drug substances lists that govern what compounding pharmacies can legally use. The 503A bulk drug substances list (21 CFR 216.23) and the 503B list (21 CFR 216.24) define what a compounding pharmacy may use to make a patient-specific or office-use preparation under federal law, and AOD-9604 is not on either list ^[5][6]. Compounding under section 503A of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 353a, is limited to specific categories of bulk substances and specific prescriber-patient relationships ^[8]. The FDA maintains a public page describing this bulk substances framework directly ^[9]. Practically, that means any product sold as "AOD-9604" or "ipamorelin" for human injection, for weight loss, anti-aging, or muscle gain, is being sold outside the framework that makes a drug legal to market for those uses. Research-use-only sales exist in a gray zone: legal to sell as a laboratory reagent, not legal to market with instructions for human dosing or with intended-use claims. The FDA's own definition of "intended uses" at 21 CFR 201.128 explains how labeling, marketing claims, and even a company's public statements can establish intended use regardless of a disclaimer printed on the vial ^[10]. A "research use only" label doesn't protect a seller who also markets dosing charts and fat-loss claims. If you're checking whether a product you're looking at is FDA-approved for any indication, Drugs@FDA is the actual government database to search, not a supplement retailer's claims page ^[11].

Will AOD-9604 or ipamorelin show up on a drug test?

For competitive athletes, this matters more than most buyers realize. AOD-9604 was specifically tested against the World Anti-Doping Agency's hGH isoform immunoassay, the test WADA uses to catch GH doping, and a 2013 study in Drug Testing and Analysis found that AOD-9604 does not influence that isoform test ^[7]. That doesn't mean it's undetectable or permitted; it means it doesn't cross-react with that particular assay, so a different, peptide-specific detection method is needed to catch it. And that peptide-specific detection exists. Analytical chemistry work describes methods built specifically to catch small peptides like AOD-9604 and GH secretagogues in doping control, including a 2016 method in Journal of Separation Science describing direct urine injection combined with liquid chromatography and ion mobility mass spectrometry to screen for peptides under 2 kDa, a size range that covers both AOD-9604 and ipamorelin ^[12]. The takeaway for anyone subject to testing: assume both peptides are detectable by modern anti-doping labs using peptide-specific methods, even though AOD-9604 slips past the older isoform-based GH test. "It won't show up on the isoform test" is a technically true but practically misleading claim if the panel being used includes newer LC-MS methods, which most WADA-accredited labs now do.

Which one has better evidence for fat loss, AOD-9604 or ipamorelin?

Neither has strong, independent, peer-reviewed human evidence specifically for fat loss as a primary endpoint, at the doses and populations people are actually buying these for online. AOD-9604's fat-loss evidence is the more direct comparison because it was actually taken into obesity-focused clinical development, and the result was a program that didn't produce a convincing separation from placebo ^[1][2]. That's a real answer, not an absence of data. The trial was attempted and it didn't deliver the effect size needed to become an approved obesity drug. Ipamorelin's fat-loss evidence is more indirect: it's inferred from its GH-releasing mechanism plus the general (and separately debated) literature on GH's role in body composition, rather than from a dedicated large trial testing ipamorelin against placebo for weight or fat loss in the population buying it online. Current peptide therapeutics reviews in orthopedics and sports medicine treat it as an unapproved compound used off-label, generally discussed in a recovery or performance context rather than as an established fat-loss agent ^[3][4]. If you're ranking by "has this specific compound been tested against placebo for fat loss in humans and shown a real effect," the honest answer for both is no. AOD-9604 got closer to that test and the result wasn't compelling. Ipamorelin hasn't really been through that specific test in a way the current literature documents clearly.

What are the side effects and safety concerns for each?

Injection site reactions (redness, swelling, mild bruising) are the most consistently reported issue for both peptide classes, as with almost any subcutaneous peptide. Beyond that, the two compounds diverge because their mechanisms diverge. AOD-9604's fragment design was specifically meant to avoid GH's effects on blood sugar and cell growth signaling, since it strips out the domain responsible for those effects, according to the rationale described in its early development literature ^[1]. Whether that holds up as a practical safety advantage over full-length GH in real-world, non-trial use isn't something the published record settles definitively, since the compound never reached a large enough trial population to characterize rare adverse events with confidence. Ipamorelin, by raising endogenous GH and downstream IGF-1, carries the theoretical side-effect profile associated with elevated GH activity: potential effects on blood sugar regulation, fluid retention, and joint or nerve symptoms some users report at higher doses, though a compound-specific large safety trial isn't part of the current published record either. For a full rundown of what's actually reported for AOD-9604 specifically, see the AOD 9604 peptide side effects page. Because neither compound has gone through the kind of large, controlled, multi-year safety trial that FDA approval requires, long-term safety data for either one, at the doses people actually use outside of a clinical trial, doesn't really exist in the peer-reviewed literature. That's a genuine gap, not a minor caveat.

How are AOD-9604 and ipamorelin typically dosed, and does that difference matter?

AOD-9604 protocols discussed in the research and enthusiast literature typically describe daily subcutaneous injections in the range of a few hundred micrograms, timed away from meals to avoid blunting the intended lipolytic signal. Ipamorelin protocols typically describe similarly small subcutaneous doses, often timed before bed or before meals to align with the body's natural GH pulse pattern, sometimes stacked with a growth hormone releasing hormone analog to amplify the pituitary signal. The practical difference is that ipamorelin's dosing logic follows a well-mapped physiological rhythm (natural GH pulses happen predominantly during deep sleep), while AOD-9604's dosing logic follows a narrower and less independently replicated rationale about avoiding meal-time blood sugar interference. Neither dosing schedule comes from a large, published, dose-ranging human trial establishing an optimal, safety-validated regimen for fat loss specifically. If you're trying to work out actual numbers rather than theory, the AOD 9604 dosage page and the AOD 9604 dosage calculator walk through the commonly cited ranges and how to think about reconstitution, alongside the AOD 9604 how to reconstitute guide for the practical mixing steps.

Should you buy AOD-9604 or ipamorelin, or neither?

If your goal is documented, peer-reviewed, placebo-beating fat loss in humans, neither compound clears that bar on the current published record. That's not a hedge, it's the actual state of the literature as of the reviews cited throughout this piece ^[1][3][4][2]. If you're going to use either one anyway, understand what you're actually buying: an unapproved research compound, not on the FDA's 503A or 503B bulk substances lists ^[5][6], sold outside the prescription drug framework, with no long-term safety trial behind it. That's true whether the seller calls it "research use only" or markets it with a dosing chart, and the FDA's intended-use rule means marketing language can matter more than the label ^[10]. What we'd actually do: treat both as experimental. If cost and effort matter to you, ipamorelin has the more physiologically coherent rationale (it triggers a real, measurable hormonal event, GH release) even though the fat-loss-specific trial data is thin. AOD-9604 has the more targeted rationale on paper but the weaker practical track record, since it was actually tested in obesity trials and didn't produce a clean win over placebo. Nobody should be paying for either one expecting GLP-1-drug-level results; that comparison isn't close, and it isn't the honest one to make.

Where AOD-9604 fits if you're going to source it anyway

If you've weighed the trial record above and still want to proceed, sourcing quality is the next real risk. Unregulated peptide markets have well-documented purity and mislabeling problems, and a product that isn't on the FDA's bulk substances list isn't getting the oversight a compounding pharmacy would normally apply under 21 U.S.C. 353a ^[8]. AOD-9604 Co reviews provider-sourced routes and points readers toward pharmacy-fulfilled options rather than unregulated retail listings, which at minimum puts a licensed pharmacy between you and the vial. Start with the AOD 9604 peptide overview if you haven't read the full mechanism and trial breakdown yet, and check the AOD 9604 peptide for sale page for how that provider-reviewed sourcing process actually works before you buy anything.

Frequently asked questions

Is AOD-9604 the same thing as ipamorelin?

No. AOD-9604 is a 15-amino-acid fragment of human growth hormone's fat-metabolism region. Ipamorelin is a 5-amino-acid growth hormone secretagogue that prompts the pituitary to release the body's own GH. They're structurally and mechanically different compounds, just both marketed for similar fat-loss and body composition goals.

Did AOD-9604 pass its human clinical trials for weight loss?

It went through clinical development for obesity, but the weight-loss results did not separate convincingly from placebo, according to the development literature from that era ^[1]. It never reached FDA approval for obesity or any other use, and no large published RCT shows a clear placebo-beating effect.

Is ipamorelin better studied than AOD-9604 for fat loss?

Not really, in terms of dedicated fat-loss trials. Ipamorelin's evidence is mostly built on its mechanism (reliable GH release) rather than a large trial proving fat loss specifically. AOD-9604 actually went through obesity-focused development and the result was an unconvincing separation from placebo, which is a different but not clearly stronger evidence position.

Will AOD-9604 show up on a WADA drug test?

A 2013 study found AOD-9604 does not trigger the WADA hGH isoform immunoassay ^[4], but modern anti-doping labs use separate peptide-specific LC-MS methods capable of detecting small peptides like AOD-9604, so assume it's detectable by a full modern testing panel ^[10].

Is ipamorelin FDA-approved?

No. Ipamorelin is not FDA-approved for any indication and doesn't appear on the FDA's Drugs@FDA database of approved products ^[12]. It's also not on the FDA's 503A or 503B bulk drug substances lists that govern legal compounding use ^[6][7].

Are AOD-9604 and ipamorelin legal to buy?

Both exist in a gray zone. They're not FDA-approved drugs and aren't on the bulk substances lists that let compounding pharmacies use them legally ^[6][7]. Products sold with human dosing instructions or fat-loss marketing claims fall outside the 'research use only' protection, per FDA's intended-use rule ^[11].

Which has fewer side effects, AOD-9604 or ipamorelin?

Neither has a large published safety trial establishing a clear side-effect profile at real-world doses. AOD-9604's fragment design was intended to avoid GH's blood sugar effects; ipamorelin raises real GH and IGF-1, carrying that hormone axis's theoretical risks. Injection site reactions are the most consistently reported issue for both.

Can you stack AOD-9604 and ipamorelin together?

People discuss stacking them because they work through different mechanisms (a GH fragment versus a GH secretagogue), but no published human trial has tested the combination for safety or fat-loss efficacy. Combining two under-studied compounds compounds the uncertainty rather than resolving it.

How is AOD-9604 dosed compared to ipamorelin?

AOD-9604 protocols in the enthusiast literature typically use daily subcutaneous doses in the hundreds-of-micrograms range, timed away from meals. Ipamorelin protocols typically use similarly small doses, often timed to align with nighttime GH pulses. Neither schedule comes from a large published dose-ranging trial specific to fat loss.

Does AOD-9604 raise blood sugar like full growth hormone does?

The fragment was designed specifically to exclude the part of the GH molecule linked to blood sugar effects, according to its early development rationale ^[1]. Whether this holds up reliably outside trial conditions isn't settled in the published literature, since AOD-9604 never reached a large enough trial population to fully characterize this.

What's the actual best-evidenced alternative to both of these for fat loss?

This article focuses on AOD-9604 versus ipamorelin specifically, and neither has strong placebo-controlled fat-loss trial data. For readers weighing all options, FDA-approved GLP-1 and dual-agonist obesity medications have a substantially larger and more rigorous trial record; check Drugs@FDA for current approved obesity treatments ^[12].

Why did AOD-9604 fail to become an approved obesity drug?

Published reviews describe its clinical development but the weight-loss effect didn't separate convincingly from placebo in the trial program ^[1], which is generally the bar FDA approval requires. It was part of a broader wave of obesity drug candidates in that era, most of which also didn't reach approval ^[5].

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): AOD-9604 is a GH fragment developed as a metabolic/fat-loss candidate; its clinical development did not produce a convincing placebo-beating result.
2. PubMed, JAAOS Global Research & Reviews (2026): Reviews therapeutic peptides including GH secretagogues like ipamorelin as unapproved compounds used off-label in orthopedic/performance contexts.
3. PubMed, Sports Medicine (2026): Covers safety and efficacy of approved and unapproved peptide therapies, including GH secretagogues, for musculoskeletal injury and athletic performance.
4. PubMed, Drug Testing and Analysis (2013): AOD-9604 does not influence the WADA hGH isoform immunoassay used in anti-doping testing.
5. PubMed, Current Opinion in Investigational Drugs (2006): Reviews obesity drugs in clinical development during that era, situating AOD-9604 among candidates that largely did not reach approval.
6. eCFR, 21 CFR 216.23 (503A Bulks List): AOD-9604 and ipamorelin are not on the FDA's 503A bulk drug substances list governing legal compounding.
7. eCFR, 21 CFR 216.24 (503B Bulks List): AOD-9604 and ipamorelin are not on the FDA's 503B bulk drug substances list for outsourcing facilities.
8. Cornell Law/Legal Information Institute, 21 U.S.C. 353a: Federal law restricts pharmacy compounding to specific bulk substances and prescriber-patient relationships under section 503A.
9. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Describes the FDA framework governing which bulk substances compounding pharmacies may legally use.
10. PubMed, Journal of Separation Science (2016): Describes an LC and ion mobility mass spectrometry method for screening peptides under 2 kDa, a size class covering AOD-9604 and ipamorelin, in doping control.
11. eCFR, 21 CFR 201.128 (Intended Uses): Defines how marketing claims and labeling establish a product's intended use regardless of a research-use-only disclaimer.
12. FDA, Drugs@FDA database: The official government database for checking whether a drug product is FDA-approved for any indication.